Cannabidiol in Children With Refractory Epileptic Encephalopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-26

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the safety and tolerability of a cannabidiol-enriched Cannabis Herbal Extract in a small group of children with refractory epileptic encephalopathy. The dosage of Cannabis Herbal Extract will be gradually increased over a four month time period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cannabidiol for Drug Resistant Pediatric Epilepsy (Expanded Access Use)

NCT03676049

Drug Resistant Epilepsy

AVAILABLE

Cannabis Extract in Refractory Epilepsy Study

NCT03808935

Drug Resistant Epilepsy

TERMINATED PHASE3

Study of Cannabidiol for Drug-Resistant Epilepsies

NCT03014440

Drug Resistant Epilepsy

NO_LONGER_AVAILABLE

CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children

NCT07023744

Drug Resistant Epilepsy

NOT_YET_RECRUITING PHASE2

Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy

NCT02286986

Epilepsy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Epileptic Encephalopathies are a group of epilepsies that develop in children. These epilepsies can cause frequent and difficult to control seizures. Because of the ongoing seizures, these epilepsies can also cause cognitive impairment and neurological impairment.

In many children with these Epileptic Encephalopathies, seizures are difficult to control with medical treatment, such as anti-convulsants or non-drug treatments like the ketogenic diet (a high fat, adequate-protein, low-carbohydrate diet). This has resulted in a need to find therapies that are effective and better tolerated for children with epileptic encephalopathies.

There is very limited data regarding the use of cannabis products in children, in particular cannabidiol-enriched cannabis oil in children with epilepsy. However, hemp oil products with high cannabidiol and low tetrahydrocannabinol ratios have been reported to provide seizure relief and cognitive improvement in children who take them.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epileptic Encephalopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Medical Cannabis Oil

CanniMed® 1:20

Group Type EXPERIMENTAL

CanniMed® 1:20

Intervention Type DRUG

A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CanniMed® 1:20

A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Medical Cannabis Oil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 1-10 years
* Epileptic Encephalopathy
* A minimum of at least 1 major seizure per week or 4 major seizures per month. For the purposes of this research study, a major seizure would include atonic, tonic, clonic, tonic-clonic, major myoclonic, myoclonic astatic seizures and epileptic spasms (including infantile spasms)
* Refractory to anticonvulsant medication as per the International League Against Epilepsy (ILAE) Definition of failing 2 appropriate anticonvulsants at therapeutic doses
* The ability to attend appointments regularly
* Negative pregnancy test at screening for females who have reached menarche

Exclusion Criteria

* Recent (\<1 month) change in anticonvulsant therapies including anticonvulsant medications, ketogenic diet or settings on Vagal Nerve Stimulator
* Recent (\<6 months) change in intravenous immunoglobulin (IVIG) treatment
* Initiation of ketogenic diet within 6 months (Patients must be on the ketogenic diet for at least 6 months to prevent any delayed response from the ketogenic diet affecting study results)
* Implantation and activation of Vagal Nerve Stimulator within 12 months (Patients may have a vagal nerve stimulator for at least one year once again to prevent delayed response from the vagal nerve stimulator affecting study results)
* Use of cannabis-based therapy within 2 months (Participants who have previously used a cannabis based therapy may be included if they have a 2 month period without use of cannabis based therapy prior to enrolment in the study)
* Use of selective serotonin reuptake inhibitor (SSRI), tricyclic antidepressant or atypical neuroleptic medication in last month
* Concomitant regular use of narcotics (Use of narcotics in emergency situations and supervised by a physician is allowed)
* Initiation or dosage change of oral or injected steroids within 3 months
* Allergy or known intolerance to any of the compounds within the study preparation
* Inability of study participants to attend assessments on a monthly basis
* Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator)

Minimum Eligible Age

1 Year

Maximum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No